

# EUS-B-FNA for left adrenal gland analysis in lung cancer patients.

Published: 11-12-2014

Last updated: 22-04-2024

The proportion of patients with a successful EUS-B-FNA procedure for LAG analysis

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Respiratory tract neoplasms
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON42163

### Source

ToetsingOnline

### Brief title

EUS-B-FNA for left adrenal gland analysis

### Condition

- Respiratory tract neoplasms

### Synonym

lung cancer

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

### Intervention

**Keyword:** EUS, EUS-B, left adrenal gland, lung cancer

## Outcome measures

### Primary outcome

The proportion of patients with a successful EUS-B-FNA procedure for LAG analysis.

### Secondary outcome

Sensitivity EUS-B-FNA and EUS-FNA for LAG metastases.

## Study description

### Background summary

The adrenal glands are a predilection site for lung cancer metastases. However, even in a patient with a known malignancy an adrenal lesion is still more likely to be benign than to be malignant. Normally the conventional EUS scope is used for left adrenal gland analysis.

The aim of this study is investigate the sensitivity EUS-B-FNA (EBUS scope) for left adrenal metastases in lung cancer patients with a suspect left adrenal gland based on imaging.

### Study objective

The proportion of patients with a successful EUS-B-FNA procedure for LAG analysis

### Study design

A prospective cohort design

### Study burden and risks

Distant metastases like LAG metastases have significant impact on prognosis and treatment. In the majority of patients, evaluation of the mediastinal nodes with the EBUS scope is also indicated. In case the LAG can be evaluated with the same scope, patients can be evaluated with a single instead of two scopes. This will be beneficial for patients (reduced investigation time) and cost \* effective. So far EUS-B of LAG has been shown to be safe and feasible.

## Contacts

### Public

Academisch Medisch Centrum

meibergdreef 9  
amsterdam 1105 AZ  
NL

### Scientific

Academisch Medisch Centrum

meibergdreef 9  
amsterdam 1105 AZ  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

lung cancer  
suspected left adrenal gland on imaging

### Exclusion criteria

contraindication for EUS/EUS-B

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 11-03-2015

Enrollment: 40

Type: Actual

## Ethics review

Approved WMO

Date: 11-12-2014

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 21-04-2015

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 07-09-2015

Application type: Amendment

Review commission: METC Amsterdam UMC

## Study registrations

## **Followed up by the following (possibly more current) registration**

No registrations found.

## **Other (possibly less up-to-date) registrations in this register**

No registrations found.

## **In other registers**

<b>Register</b>	<b>ID</b>
CCMO	NL50139.018.14